Linked Life Data

1695325

Source:http://linkedlifedata.com/resource/pubmed/id/1695325

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1990-8-23
pubmed:abstractText
Hydroxyurea increases the production of fetal hemoglobin (hemoglobin F) in patients with sickle cell anemia and therefore has the potential for alleviating both the hemolytic and vaso-occlusive manifestations of the disease. There is preliminary evidence that recombinant human erythropoietin may also increase hemoglobin F production. METHODS and
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0028-4793
pubmed:author
pubmed:issnType
Print
pubmed:day
9
pubmed:volume
323
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
366-72
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
pubmed:affiliation
Department of Medicine, Brigham and Women's Hospital, MA 02115.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't